Generic Name: rilpivirine

Pronunciation: N/A

Abbreviation: RPV

Other Market Name: N/A

Drug Class: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Company: Janssen Therapeutics

Approval Status: Approved

Generic Version Available: No

Experimental Code: TMC-278


Drug Indication

A component of alternative treatment regimens for antiretroviral-naive people living with HIV, as indicated by the U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Visit https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0 for the full DHHS guidelines.


General Info

Edurant is an HIV medication. It is in a category of HIV medicines called non-nucleoside reverse transcriptase inhibitors. Edurant was approved by the U.S. Food and Drug Administration for use by people living with HIV in May 2011.

Edurant is approved for HIV-positive people starting treatment for the first time. It should not be taken with other NNRTIs.

Edurant is available as a single drug or in the fixed-dose combination drug, Complera.

Edurant must be used in combination with other HIV drugs.


Dosage

Adult Dose: One 25mg tablet once a day.

Pediatric Dose: N/A

Dosing Info: Take with food.


Side Effects

Common side effects of Edurant include trouble sleeping (insomnia), headache and rash.

Edurant can cause depression or mood changes. Be sure to contact your health care provider immediately if you are feeling said or hopeless, feeling anxious or restless, or have thoughts of hurting yourself (suicide) or have tried to hurt yourself.

At doses above 25mg, which may be necessary to treat people with HIV resistance to other NNRTIs (not currently recommended), Edurant was found to disturb the heart’s rhythm, a syndrome called QT-prolongation.


Drug Interactions

For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Edurant or may require dose adjustments, consult the Edurant package insert: http://www.edurant.com/shared/product/Edurant/EDURANT-PI.pdf


Other Info

Before taking this medication, tell your doctor if you have kidney disease, liver disease (including hepatitis B), or a history of depression/suicidal thoughts. In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.


For More Info: http://www.edurant.com/shared/product/Edurant/EDURANT-PI.pdf

Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Last Reviewed: July 15, 2016